Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00537-186003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Zheng Xin Dong	
(37 CFR §1.98(b))		Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,705,483	01/06/98	Galloway et al.			
	AB	5,545,618	08/13/96	Buckley et al.			
	AC						
	AD						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	AE	HU P9501508	02/28/97	Hungary				
	AF	WO 87/06941	11/19/87	PCT				
	AG	WO 91/11457	08/08/91	PCT				
	AH	0 658 568 A1	06/21/95	Europe				
	AI	0 699 686 A2 & A3	03/06/96	Europe				
	AJ	0 708 179 A2 & A3	04/24/96	Europe				
	AK	0 733 644 A1	09/25/96	Europe				
	AL	WO 97/29180	08/14/97	PCT				
	AM	WO 98/03547	01/29/98	PCT				
	AN	WO 98/08871	03/05/98	PCT				
	AO	WO 98/19698	05/14/98	PCT				
	AP	0 869 135 A1	10/07/98	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	Gutniak, Mark, et al.; "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus"; 1992; The New England Journal of Medicine; Vol. 326 No. 20; Pages 1316-1322
	AR	Mentlein, R., et al; "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, Glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation *in* human serum"; 1993; Biochem; Vol. 214; Pages 829-835
	AS	Nauck, M. A., et al.; "Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide))in patients with NIDDM"; 1996; Diabetologia; Vol. 82: 2; Pages 1546-1553

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00537-186003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Zheng Xin Dong	
		Filing Date	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AT	Parker, J. C., et al.; "Structure-function analysis of a series of glucagon-like peptide-l analogs"; 1998: Peptide Res; Vol. 52: 5; Pages 398-409; XP-000788444
	AU	Rachman, J., et al.; "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-l (GLP-1)in subjects with NIDDM"; 1997; Diabetologia; Vol. 40; Pages 205-211
	AV	Suzuki, S., et al.; "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-l on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas"; 1989; Endocrinology; Vol. 125: 6; Pages 3109-3114
	AW	Thorens, Bernard, et al.; "Glucagon-Like Peptide-and the Control of Insulin Secretion in the Normal State and in NIDDM"; 1993; Diabetes; Vol. 42: Pages 1219-1225
	AX	Thorens, Bernard, et al.; "Structure and Function of the Glucagon-Like Peptide-l Receptor"; 1996; Handbook of Experimental Pharmacology; Vol. 123; Pages 255-273
	AY	Todd, J. F., et al.; "Glucagon-like peptide-l (GLP-1): a trial Of treatment in non-insulin-dependent diabetes mellitus"; 1997; European Journal of Clinical Investigation; Vol. 27; Pages 533-536
	AZ	Ahren, Bo, et al.; "Effects of Glucagon-Like Peptide-l on Islet. Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus"; 1997; Journal of Clinical Endocrinology and Metabolism; Vo1.82: 2; Pages 473-478
	AAA	Deacon, C-F., et al.; "Dipeptidyl. peptidase IV resistant analogues of glucagon-like peptide-l which have extended metabolic stability and improved biological activity": 1998; Diabetologia; Vol. 41; Pages, 271-278
	ABB	Deacon, C. F., et al.; "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig"; 1998; Diabetes; Vol. 47; Pages 764-769

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	